25665 Efficacy and safety of mirikizumab in psoriasis: 52-week results from the OASIS-1 randomized controlled trial

Authors
Category Primary study
JournalJournal of the American Academy of Dermatology
Year 2021
This article has no abstract
Epistemonikos ID: d970d33db711d9dbe39c4c585bf3984e70a50361
First added on: Feb 13, 2025